Left Bundle Branch BlockNCT02283619
Left Bundle Branch Block ECG Characteristics in the Evaluation of Acute Coronary Syndrome
An observational study of Left Bundle Branch Block, run by Duke University.
Trial summary
Purpose of the study: The goal of this study is to evaluate the relationship of electrocardiogram (ECG) findings with clinical outcomes in a cohort of patients with left bundle branch block (LBBB) who are being evaluated for acute coronary syndrome (ACS) in the Emergency Department (ED). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Left Bundle Branch Block
- How many people
- 8 participants
- Where
- No sites listed yet
- Study dates
- Nov 2014to Aug 2015
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Selection of Subjects: The population will be patients age 18 or older who present to the ED with LBBB and suspected ACS. The investigators expect the mean age of the population to be approximately 60 years old, with most patients between 40 and 90. They anticipate that these patients will on average have multiple medical comorbidities given that those with LBBB and ACS are reported to be a sicker, older population with more cardiac risk factors than the usual ACS patient without LBBB. Patients under age 18 will be excluded because they extremely rarely have ACS and/or LBBB.
Who may be able to join
- Age 18 and older
- LBBB on ECG
- Presenting to the ED and being evaluated for ACS
Who cannot join
- Prisoners
- Institutionalized individuals
- Patients who are incapable of giving legally effective consent
- Patients who cannot understand spoken English
About this study
Official title: Correlation of Clinical Outcomes With ECG Findings in Patients With Left Bundle Branch Block Being Evaluated for Acute Coronary Syndrome - a Prospective Cohort Study
Purpose of the study:
The goal of this study is to evaluate the relationship of electrocardiogram (ECG) findings with clinical outcomes in a cohort of patients with left bundle branch block (LBBB) who are being evaluated for acute coronary syndrome (ACS) in the Emergency Department (ED).
Read more
Background and significance:
The significance of specific ECG findings in patients with LBBB being evaluated for ACS has been inadequately studied, and this gap in knowledge is a barrier to optimal management of this population. Due to the speed, availability, low cost, and non-invasive nature of the ECG, it would be ideal to identify ECG characteristics that help to risk stratify these patients in order to inform clinical decision-making, reduce unnecessary invasive testing, and conserve resources.
Methods:
In this prospective observational study the investigators will identify a consecutive series of adult patients with LBBB presenting to the ED with suspicion of ACS. The investigators will collect data including demographics, cardiac risk factors, initial ECG measurements, lab and radiographic results, procedure results, and clinical outcomes such as 30-day death or myocardial infarction (MI). The investigators will analyze the data using a cohort study design to calculate odds ratios between ECG characteristics and the outcomes of interest.
Read the detailed description
Purpose of the study:
The goal of this study is to identify initial electrocardiogram (ECG) findings (including ST/S ratio and T-wave morphology) that predict clinical outcomes (myocardial infarction, positive stress test, revascularization and death), in a cohort of Emergency Department (ED) patients with left bundle branch block (LBBB) who are being evaluated for acute coronary syndrome (ACS).
Design \& procedures:
The investigators will prospectively identify all adult (18yrs and older) patients presenting to their institution's ED who are being evaluated for ACS and have LBBB on ECG. The investigators will collect data on demographics (including age, but not date of birth), cardiac risk factors, date and time of presentation to the ED, ECG measurements, lab and radiographic results (cardiac biomarker data including date and time of the sample, stress test results, coronary imaging results, coronary catheterization results) and clinical outcomes such as 30-day death or MI. They will collect copies of ECGs and measure the following: ST/S ratio (ratio of the amplitude of ST segment deviation to the S wave amplitude); T-wave morphology (entirely discordant, entirely concordant, or biphasic to the PR interval); and standard ST segment deviation. A logistic regression analysis will be used to identify which ECG features are associated with 30-day death, MI, and revascularization. In the sub-cohort of subjects with negative "modified Sgarbossa criteria" a subanalysis will identify the outcome rates for the following specific sub-populations: those less than 2 consecutive partially-concordant T-wave leads and those with 2 or more consecutive partially-concordant T-wave leads.
Selection of Subjects:
The population will be patients age 18 or older who present to the ED with LBBB and suspected ACS. The investigators expect the mean age of the study population to be approximately 60 years old, with most patients between 40 and 90. They anticipate that these patients will on average have multiple medical comorbidities given that those with LBBB and ACS are reported to be a sicker, older population with more cardiac risk factors than the usual ACS patient without LBBB. Patients under age 18 will be excluded because they extremely rarely have ACS and/or LBBB. The investigators anticipate 300 subjects.
Inclusion criteria: age 18 and older, LBBB on ECG, presenting to the ED and being evaluated for ACS.
Exclusion criteria: prisoners, institutionalized individuals, patients who are incapable of giving legally effective consent, patients who cannot understand spoken English.
Consent process:
After the initial screening process, if the potential subject meets the inclusion/exclusion criteria and does not object to learning more about the study during initial discussion with their primary provider, then one of the key personnel trained and authorized to consent will approach the potential subject to discuss the study by explaining the following: the purpose of the study and the future benefits it may provide in subsequent patients, the prospective and observational nature of the study, the study procedures, the risks of loss of confidentiality, and the safeguards against that risk. All information will be clearly printed in plain language on the consent form. The potential subject will then be given the choice to enroll in the study.
Only the potential subject will be allowed to provide consent. The potential subject will have until discharge or transfer from the Emergency Department to decide whether or not to participate in the study. The minimal risks and minimal subject involvement justify this practical and logical time requirement. The consent process will occur in the potential subject's room in the Emergency Department.
Data Analysis \& Statistical Considerations:
The data will be analyzed with a cohort study design, calculating odds ratios between ECG characteristics and outcomes. The two primary ECG characteristics investigated will be 1) presence of at least 2 consecutive leads with at least a partially concordant T-wave (biphasic or entirely concordant), and 2) the ST/S ratio (the ratio of the ST-segment deviation to the S or R wave amplitude, whichever greater). Secondary ECG features measured will include heart rate, rhythm, intervals, bundle branch blocks, PR and ST segment deviations and concordance/discordance, P/Q/R/S/T amplitudes, QRS durations, QT intervals, T wave inversions, segment contours and concavity/convexity. The primary outcomes of interest will be 1) positive cardiac troponin T biomarker levels on index visit, and 2) positive stress test results on index visit. Secondary outcomes will include the rates of 30-day myocardial infarction, 30-day death, and 30-day revascularization.
The investigators will present summary statistics on subject demographics, ECG findings, lab/imaging/procedure results, and outcomes. They will determine association between dichotomous outcomes of cardiac biomarker (cTNT) levels, stress test, MI, death, revascularization, and normally distributed continuous clinical and demographic characteristics using t-tests for normally distributed continuous data or Wilcoxon tests for non-normally distributed data, and with categorical characteristics using Fisher's exact or Chi-squared tests. Associations between continuous variables will be assessed using Spearman or Pearson correlations. Significance of the tests will be assessed at alpha = 0.05. Analysis will be conducted using SAS 9.3 (SAS Institute, Inc., Cary, NC).
- Conditions
- Left Bundle Branch Block
- Being tested
- None - no intervention, observational study
- Medical subject headings
- Bundle-Branch Block
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
None - no intervention, observational studyOther
No intervention, observational study
| Study group | Role | What they receive |
|---|---|---|
| Patients with LBBB being evaluated for ACS | Patients who present to the emergency department with left bundle branch block on the electrocardiogram, who are being evaluated for acute coronary syndrome, and who qualify based on the inclusion/exclusion criteria listed in the detailed description. Receives: Other: None - no intervention, observational study |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sensitivity of non-discordant T waves for prediction of positive cardiac biomarkers on index visit
Diagnostic properties (sensitivity, specificity, likelihood ratios) of item 1 for item 2 below:
- Presence of at least two ECG leads with non-discordant T waves (meaning either entirely concordant or biphasic, relative to the PR interval)
- Positive (above the assay's normal reference range) cardiac biomarkers (cardiac troponin I, T, or CK-MB) within 48 hours of presentation to the ED.
Measured: The ECG will be the ECG on presentation to the ED. The maximum cardiac troponin within 48 hours of index visit will be used as the outcome.
Specificity of non-discordant T waves for prediction of positive cardiac biomarkers on index visit
Diagnostic properties (sensitivity, specificity, likelihood ratios) of item 1 for item 2 below:
- Presence of at least two ECG leads with non-discordant T waves (meaning either entirely concordant or biphasic, relative to the PR interval)
- Positive (above the assay's normal reference range) cardiac biomarkers (cardiac troponin I, T, or CK-MB) within 48 hours of presentation to the ED.
Measured: The ECG will be the ECG on presentation to the ED. The maximum cardiac troponin within 48 hours of index visit will be used as the outcome.
Positive likelihood ratio of non-discordant T waves for prediction of positive cardiac biomarkers on index visit
Diagnostic properties (sensitivity, specificity, likelihood ratios) of item 1 for item 2 below:
- Presence of at least two ECG leads with non-discordant T waves (meaning either entirely concordant or biphasic, relative to the PR interval)
- Positive (above the assay's normal reference range) cardiac biomarkers (cardiac troponin I, T, or CK-MB) within 48 hours of presentation to the ED.
Measured: The ECG will be the ECG on presentation to the ED. The maximum cardiac troponin within 48 hours of index visit will be used as the outcome.
Negative likelihood ratio of non-discordant T waves for prediction of positive cardiac biomarkers on index visit
Diagnostic properties (sensitivity, specificity, likelihood ratios) of item 1 for item 2 below:
- Presence of at least two ECG leads with non-discordant T waves (meaning either entirely concordant or biphasic, relative to the PR interval)
- Positive (above the assay's normal reference range) cardiac biomarkers (cardiac troponin I, T, or CK-MB) within 48 hours of presentation to the ED.
Measured: The ECG will be the ECG on presentation to the ED. The maximum cardiac troponin within 48 hours of index visit will be used as the outcome.
Secondary outcomes (4)
Sensitivity of various exploratory ECG findings for positive cardiac biomarkers
Logistic regression will be used to test multiple ECG measurements (other than the primary outcome, listed above) for diagnostic utility to predict positive cardiac biomarkers. Potentially relevant ECG findings will be explored via an ROC curve to find optimal cutpoints for diagnostic accuracy, and presented by means of diagnostic properties including sensitivity, specificity, and likelihood ratios. These findings will be explicitly listed as post-hoc, exploratory findings meant only to direct further research.
Measured: The ECG measurements at presentation to the ED will be used, to predict maximum cardiac troponin within 48 hours of presentation to the ED.
Specificity of various exploratory ECG findings for positive cardiac biomarkers
Logistic regression will be used to test multiple ECG measurements (other than the primary outcome, listed above) for diagnostic utility to predict positive cardiac biomarkers. Potentially relevant ECG findings will be explored via an ROC curve to find optimal cutpoints for diagnostic accuracy, and presented by means of diagnostic properties including sensitivity, specificity, and likelihood ratios. These findings will be explicitly listed as post-hoc, exploratory findings meant only to direct further research.
Measured: The ECG measurements at presentation to the ED will be used, to predict maximum cardiac troponin within 48 hours of presentation to the ED.
Positive likelihood ratio of various exploratory ECG findings for positive cardiac biomarkers
Logistic regression will be used to test multiple ECG measurements (other than the primary outcome, listed above) for diagnostic utility to predict positive cardiac biomarkers. Potentially relevant ECG findings will be explored via an ROC curve to find optimal cutpoints for diagnostic accuracy, and presented by means of diagnostic properties including sensitivity, specificity, and likelihood ratios. These findings will be explicitly listed as post-hoc, exploratory findings meant only to direct further research.
Measured: The ECG measurements at presentation to the ED will be used, to predict maximum cardiac troponin within 48 hours of presentation to the ED.
Negative likelihood ratio of various exploratory ECG findings for positive cardiac biomarkers
Logistic regression will be used to test multiple ECG measurements (other than the primary outcome, listed above) for diagnostic utility to predict positive cardiac biomarkers. Potentially relevant ECG findings will be explored via an ROC curve to find optimal cutpoints for diagnostic accuracy, and presented by means of diagnostic properties including sensitivity, specificity, and likelihood ratios. These findings will be explicitly listed as post-hoc, exploratory findings meant only to direct further research.
Measured: The ECG measurements at presentation to the ED will be used, to predict maximum cardiac troponin within 48 hours of presentation to the ED.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Nov 2014 (estimated)
- Study startNov 2014
- Primary completionAug 2015
- Study completionAug 2015
Why it stopped: Study was found to be non-feasible. Not enough patients to perform an adequate study in the allocated time period.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Left Bundle Branch BlockStudies of the same condition, open and under way.
- More trials run by Duke UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 8 participants (actual)
Sponsor and investigators
- Lead sponsor
- Duke University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Alexander T Limkakeng, MD, Principal investigator, Duke University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02283619
- Sponsor's protocol ID
- Pro00051429
- Status last verified
- Aug 2015
- First submitted
- 31 Oct 2014
- Last updated
- 28 Sep 2015
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Sep 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Correlation of Clinical Outcomes With ECG Findings in Patients With Left Bundle Branch Block Being Evaluated for Acute Coronary Syndrome - a Prospective Cohort Study
- ClinicalTrials.gov ID
- NCT02283619
- Acronym / sponsor ID
- Pro00051429
- Conditions
- Left Bundle Branch Block
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: Study was found to be non-feasible. Not enough patients to perform an adequate study in the allocated time period.
- Enrolment
- 8 participants (actual)
- Lead sponsor
- Duke UniversityUniversity, hospital or other
- Study start
- Nov 2014
- Primary completion
- Aug 2015 (actual)
- Study completion
- Aug 2015 (actual)
- First posted
- 5 Nov 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Purpose of the study:
The goal of this study is to evaluate the relationship of electrocardiogram (ECG) findings with clinical outcomes in a cohort of patients with left bundle branch block (LBBB) who are being evaluated for acute coronary syndrome (ACS) in the Emergency Department (ED).
Background and significance:
The significance of specific ECG findings in patients with LBBB being evaluated for ACS has been inadequately studied, and this gap in knowledge is a barrier to optimal management of this population. Due to the speed, availability, low cost, and non-invasive nature of the ECG, it would be ideal to identify ECG characteristics that help to risk stratify these patients in order to inform clinical decision-making, reduce unnecessary invasive testing, and conserve resources.
Methods:
In this prospective observational study the investigators will identify a consecutive series of adult patients with LBBB presenting to the ED with suspicion of ACS. The investigators will collect data including demographics, cardiac risk factors, initial ECG measurements, lab and radiographic results, procedure results, and clinical outcomes such as 30-day death or myocardial infarction (MI). The investigators will analyze the data using a cohort study design to calculate odds ratios between ECG characteristics and the outcomes of interest.
Detailed description
Purpose of the study:
The goal of this study is to identify initial electrocardiogram (ECG) findings (including ST/S ratio and T-wave morphology) that predict clinical outcomes (myocardial infarction, positive stress test, revascularization and death), in a cohort of Emergency Department (ED) patients with left bundle branch block (LBBB) who are being evaluated for acute coronary syndrome (ACS).
Design \& procedures:
The investigators will prospectively identify all adult (18yrs and older) patients presenting to their institution's ED who are being evaluated for ACS and have LBBB on ECG. The investigators will collect data on demographics (including age, but not date of birth), cardiac risk factors, date and time of presentation to the ED, ECG measurements, lab and radiographic results (cardiac biomarker data including date and time of the sample, stress test results, coronary imaging results, coronary catheterization results) and clinical outcomes such as 30-day death or MI. They will collect copies of ECGs and measure the following: ST/S ratio (ratio of the amplitude of ST segment deviation to the S wave amplitude); T-wave morphology (entirely discordant, entirely concordant, or biphasic to the PR interval); and standard ST segment deviation. A logistic regression analysis will be used to identify which ECG features are associated with 30-day death, MI, and revascularization. In the sub-cohort of subjects with negative "modified Sgarbossa criteria" a subanalysis will identify the outcome rates for the following specific sub-populations: those less than 2 consecutive partially-concordant T-wave leads and those with 2 or more consecutive partially-concordant T-wave leads.
Selection of Subjects:
The population will be patients age 18 or older who present to the ED with LBBB and suspected ACS. The investigators expect the mean age of the study population to be approximately 60 years old, with most patients between 40 and 90. They anticipate that these patients will on average have multiple medical comorbidities given that those with LBBB and ACS are reported to be a sicker, older population with more cardiac risk factors than the usual ACS patient without LBBB. Patients under age 18 will be excluded because they extremely rarely have ACS and/or LBBB. The investigators anticipate 300 subjects.
Inclusion criteria: age 18 and older, LBBB on ECG, presenting to the ED and being evaluated for ACS.
Exclusion criteria: prisoners, institutionalized individuals, patients who are incapable of giving legally effective consent, patients who cannot understand spoken English.
Consent process:
After the initial screening process, if the potential subject meets the inclusion/exclusion criteria and does not object to learning more about the study during initial discussion with their primary provider, then one of the key personnel trained and authorized to consent will approach the potential subject to discuss the study by explaining the following: the purpose of the study and the future benefits it may provide in subsequent patients, the prospective and observational nature of the study, the study procedures, the risks of loss of confidentiality, and the safeguards against that risk. All information will be clearly printed in plain language on the consent form. The potential subject will then be given the choice to enroll in the study.
Only the potential subject will be allowed to provide consent. The potential subject will have until discharge or transfer from the Emergency Department to decide whether or not to participate in the study. The minimal risks and minimal subject involvement justify this practical and logical time requirement. The consent process will occur in the potential subject's room in the Emergency Department.
Data Analysis \& Statistical Considerations:
The data will be analyzed with a cohort study design, calculating odds ratios between ECG characteristics and outcomes. The two primary ECG characteristics investigated will be 1) presence of at least 2 consecutive leads with at least a partially concordant T-wave (biphasic or entirely concordant), and 2) the ST/S ratio (the ratio of the ST-segment deviation to the S or R wave amplitude, whichever greater). Secondary ECG features measured will include heart rate, rhythm, intervals, bundle branch blocks, PR and ST segment deviations and concordance/discordance, P/Q/R/S/T amplitudes, QRS durations, QT intervals, T wave inversions, segment contours and concavity/convexity. The primary outcomes of interest will be 1) positive cardiac troponin T biomarker levels on index visit, and 2) positive stress test results on index visit. Secondary outcomes will include the rates of 30-day myocardial infarction, 30-day death, and 30-day revascularization.
The investigators will present summary statistics on subject demographics, ECG findings, lab/imaging/procedure results, and outcomes. They will determine association between dichotomous outcomes of cardiac biomarker (cTNT) levels, stress test, MI, death, revascularization, and normally distributed continuous clinical and demographic characteristics using t-tests for normally distributed continuous data or Wilcoxon tests for non-normally distributed data, and with categorical characteristics using Fisher's exact or Chi-squared tests. Associations between continuous variables will be assessed using Spearman or Pearson correlations. Significance of the tests will be assessed at alpha = 0.05. Analysis will be conducted using SAS 9.3 (SAS Institute, Inc., Cary, NC).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with LBBB being evaluated for ACS | – | Other: None - no intervention, observational studyPatients who present to the emergency department with left bundle branch block on the electrocardiogram, who are being evaluated for acute coronary syndrome, and who qualify based on the inclusion/exclusion criteria listed in the detailed description. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Selection of Subjects: The population will be patients age 18 or older who present to the ED with LBBB and suspected ACS. The investigators expect the mean age of the population to be approximately 60 years old, with most patients between 40 and 90. They anticipate that these patients will on average have multiple medical comorbidities given that those with LBBB and ACS are reported to be a sicker, older population with more cardiac risk factors than the usual ACS patient without LBBB. Patients under age 18 will be excluded because they extremely rarely have ACS and/or LBBB.
Key inclusion criteria (3 listed)
- Age 18 and older
- LBBB on ECG
- Presenting to the ED and being evaluated for ACS
Key exclusion criteria (4 listed)
- Prisoners
- Institutionalized individuals
- Patients who are incapable of giving legally effective consent
- Patients who cannot understand spoken English
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| None - no intervention, observational studyNo intervention, observational study | Other | Patients with LBBB being evaluated for ACS |
Primary outcome
Sensitivity of non-discordant T waves for prediction of positive cardiac biomarkers on index visit
Time frame: The ECG will be the ECG on presentation to the ED. The maximum cardiac troponin within 48 hours of index visit will be used as the outcome.
Diagnostic properties (sensitivity, specificity, likelihood ratios) of item 1 for item 2 below: 1. Presence of at least two ECG leads with non-discordant T waves (meaning either entirely concordant or biphasic, relative to the PR interval) 2. Positive (above the assay's normal reference range) cardiac biomarkers (cardiac troponin I, T, or CK-MB) within 48 hours of presentation to the ED.
Specificity of non-discordant T waves for prediction of positive cardiac biomarkers on index visit
Time frame: The ECG will be the ECG on presentation to the ED. The maximum cardiac troponin within 48 hours of index visit will be used as the outcome.
Diagnostic properties (sensitivity, specificity, likelihood ratios) of item 1 for item 2 below: 1. Presence of at least two ECG leads with non-discordant T waves (meaning either entirely concordant or biphasic, relative to the PR interval) 2. Positive (above the assay's normal reference range) cardiac biomarkers (cardiac troponin I, T, or CK-MB) within 48 hours of presentation to the ED.
Positive likelihood ratio of non-discordant T waves for prediction of positive cardiac biomarkers on index visit
Time frame: The ECG will be the ECG on presentation to the ED. The maximum cardiac troponin within 48 hours of index visit will be used as the outcome.
Diagnostic properties (sensitivity, specificity, likelihood ratios) of item 1 for item 2 below: 1. Presence of at least two ECG leads with non-discordant T waves (meaning either entirely concordant or biphasic, relative to the PR interval) 2. Positive (above the assay's normal reference range) cardiac biomarkers (cardiac troponin I, T, or CK-MB) within 48 hours of presentation to the ED.
Negative likelihood ratio of non-discordant T waves for prediction of positive cardiac biomarkers on index visit
Time frame: The ECG will be the ECG on presentation to the ED. The maximum cardiac troponin within 48 hours of index visit will be used as the outcome.
Diagnostic properties (sensitivity, specificity, likelihood ratios) of item 1 for item 2 below: 1. Presence of at least two ECG leads with non-discordant T waves (meaning either entirely concordant or biphasic, relative to the PR interval) 2. Positive (above the assay's normal reference range) cardiac biomarkers (cardiac troponin I, T, or CK-MB) within 48 hours of presentation to the ED.
4 secondary outcomes
Sensitivity of various exploratory ECG findings for positive cardiac biomarkers
Time frame: The ECG measurements at presentation to the ED will be used, to predict maximum cardiac troponin within 48 hours of presentation to the ED.
Specificity of various exploratory ECG findings for positive cardiac biomarkers
Time frame: The ECG measurements at presentation to the ED will be used, to predict maximum cardiac troponin within 48 hours of presentation to the ED.
Positive likelihood ratio of various exploratory ECG findings for positive cardiac biomarkers
Time frame: The ECG measurements at presentation to the ED will be used, to predict maximum cardiac troponin within 48 hours of presentation to the ED.
Negative likelihood ratio of various exploratory ECG findings for positive cardiac biomarkers
Time frame: The ECG measurements at presentation to the ED will be used, to predict maximum cardiac troponin within 48 hours of presentation to the ED.
Results and safety
The study was stopped early (reason given: Study was found to be non-feasible. Not enough patients to perform an adequate study in the allocated time period.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Sep 2015.
Related trials for Left Bundle Branch Block
Active, not recruitingObservational study
Safety, Performance, and Clinical Benefit of Pacing the Left Bundle Branch Area - Post-Market Clinical Follow-up
Bradycardia, Atrioventricular Block
Recruiting
Advancing Clinical Heart Failure Outcomes Leveraging Defibrillation Lead Implant System for Left Bundle Branch Area Pacing
Heart Failure, Systolic Bundle Branch Block, Left
Recruiting
Novel Approach to Conduction System Pacing With Use of Ultrasound
Conduction Block, Atrioventricular, Bundle-Branch Block
Recruiting
Clinical Monitoring Strategy Versus Electrophysiology-guided Algorithmic Approach With a New LBBB After TAVI
Left Bundle-Branch Block, Aortic Valve Stenosis
Recruiting
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
Left Bundle Branch Area Pacing, Right Ventricular Pacing
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alexander T Limkakeng, MD principal investigator
Duke University Hospital
Questions about this trial
What is this clinical trial studying?
An observational study of Left Bundle Branch Block, run by Duke University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 28 Sep 2015. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Study was found to be non-feasible. Not enough patients to perform an adequate study in the allocated time period.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sensitivity of non-discordant T waves for prediction of positive cardiac biomarkers on index visit (time frame: The ECG will be the ECG on presentation to the ED. The maximum cardiac troponin within 48 hours of index visit will be used as the outcome.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2015.